Li Pinger, Lou Yinmei
Integrated Traditional Chinese and Western Medicine, The First People's Hospital, Fuyang, Hangzhou 311400, Zhejiang, China.
Evid Based Complement Alternat Med. 2021 Dec 17;2021:2782875. doi: 10.1155/2021/2782875. eCollection 2021.
To investigate the clinical value of Fuzheng Guben anticancer decoction combined with taxol in treating ovarian carcinoma (OC).
The medical records of 80 OC patients treated in the First People's Hospital of Fuyang Hangzhou (January 2018-January 2021) were retrospectively analyzed, and the patients were split into the control group and the experimental group according to the treatment regimen, with 40 cases each. Those in the control group accepted the taxol chemotherapy, and on this basis, those in the experimental group took the Fuzheng Guben anticancer decoction, so as to compare its clinical efficacy and complication incidence.
No statistical between-group differences in patients' general information were observed ( > 0.05); compared with the control group, the disease objective remission rate of the experimental group was greatly higher ( < 0.05); before and after treatment, the changes in CD8 were not significant, indicating no statistically significant between-group differences ( > 0.05), and after treatment, CD3, CD4, and CD4/CD8 were obviously higher than before and were obviously higher in the experimental group than in the control group ( < 0.05); after treatment, the CA125, CA199, and CEA levels were obviously lower than before and were significantly lower in the experimental group than in the control group ( < 0.05); the mean survival of the experimental group was significantly higher than that of the control group (19.80 ± 5.84 vs. 14.075 ± 5.12 months, < 0.05); and between the two groups, the incidence rate of adverse reactions of the experimental group was remarkably lower ( < 0.05).
On the basis of taxol chemotherapy, jointly applying Fuzheng Guben anticancer decoction can significantly improve the clinical efficacy of OC, help to improve patients' immune function, lower the complication incidence rate, and prolong the mean survival.
探讨扶正固本抗癌汤联合紫杉醇治疗卵巢癌（OC）的临床价值。
回顾性分析2018年1月至2021年1月在杭州市富阳第一人民医院接受治疗的80例OC患者的病历资料，根据治疗方案将患者分为对照组和试验组，每组40例。对照组接受紫杉醇化疗，试验组在此基础上服用扶正固本抗癌汤，比较两组的临床疗效和并发症发生率。
患者一般资料组间比较差异无统计学意义（P>0.05）；试验组疾病客观缓解率显著高于对照组（P<0.05）；治疗前后CD8变化不明显，组间比较差异无统计学意义（P>0.05），治疗后CD3、CD4及CD4/CD8均明显高于治疗前，且试验组高于对照组（P<0.05）；治疗后CA125、CA199及CEA水平均明显低于治疗前，且试验组低于对照组（P<0.05）；试验组平均生存期显著高于对照组（19.80±5.84 vs. 14.075±5.12个月，P<0.05）；试验组不良反应发生率显著低于对照组（P<0.05）。
在紫杉醇化疗基础上联合应用扶正固本抗癌汤可显著提高OC的临床疗效，有助于提高患者免疫功能，降低并发症发生率，延长平均生存期。
